Lymphoma Clinical Trials and Research | Norton Healthcare Louisville, Ky.

Lymphoma Clinical Trials and Research

Norton Cancer Institute is at the forefront of lymphoma treatment research. As investigators on numerous trials, our specialist physicians have unparalleled experience with many innovative treatments once they are approved for broad use. Patients also may be eligible to take part in these experimental lymphoma treatments. Norton Cancer Institute researchers also contribute to groundbreaking studies and other publications in peer-reviewed journals.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Clinical Trials and Studies

B-Cell Non-Hodgkin Lymphoma

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Teneobio, Inc.

Diffuse Large B-Cell Lymphoma

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newlydiagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: MorphoSys AG

Hematological Malignancies

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Trillium Therapeutics Inc.

Leukemia

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Loxo Oncology

Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Bayer Healthcare Pharmaceuticals

Lymphoma

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Study Type: Specimen Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Celgene

Lymphoma

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.

Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Southwest Oncology Group (SWOG)

Lymphoma

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Karyopharm Therapeutics Inc.

Lymphoma

Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Lymphoma

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Artiva Biotherapeutics, Inc.

Lymphoma

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Adicet Bio, Inc

Lymphoma

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioInvent International AB

Lymphoma

An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AVM Biotechnology

Lymphoma

A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO--501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Allogene Therapeutics, Inc.

Lymphoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Incyte Corporation

Lymphoma

Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Adicet Therapeutics Inc

Lymphoma

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ADC Therapeutics SA

Primary Central Nervous System Lymphoma

An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ONO Pharmaceutical Co., Ltd.

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kymera Therapeutics, Inc

Relapsed or Refractory Diffuse Large B-Cell Lympho

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck & Co., Inc

Relapsed or Refractory Lymphomas

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kymera Therapeutics, Inc
Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

CAR-T cell therapy triggers the body’s own defenses to fight cancer

CAR-T cell therapy takes advantage of the body’s immune system to fight off cancer, much like it does already to kick the common cold and other types of illness. Our bodies don’t always fight off […]

Read Full Story

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught […]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped […]

Read Full Story
Related Stories

CAR-T cell therapy triggers the body’s own defenses to fight cancer

CAR-T cell therapy takes advantage of the body’s immune system to fight off cancer, much like it does already to kick the common cold and other types of illness. Our bodies don’t always fight off […]

Read Full Story

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught […]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.